We caution you that the foregoing list of important factors is not
exclusive. In addition, in light of these risks and uncertainties, the
matters referred to in our forward-looking statements may not occur. We
undertake no obligation to publicly update or revise any forward-looking
statement as a result of new information, future events or otherwise,
except as may be required by law.
Warner Chilcott Limited
2008 Full Year Financial Guidance
(U.S. dollars in millions, except per share information)
Total Revenue(1) $935 to $945
Gross Margin as a % of Revenue 80% to 81%
Selling & Distribution $93 to $96
A&P $62 to $65
G&A $73 to $76
Total SG&A Expenses(2) $228 to $237
Total R&D Expense $57 to $60(3)
Total Income Tax Provision 7.5% to 8% of EBTA(4)
GAAP Net Income $118 to $128
Cash Net Income ("CNI") $315 to $325(5)
CNI per Share $1.25 to $1.30(5,6)
(1) Our 2008 guidance assumes generic competition for DOVONEX solution in 1Q08 and SARAFEM in 2Q08. Our 2008 guidance does not account for the impact of any future new licensing agreements.
(2) Total SG&A expense does not include any amount that may be payable in connection with the potential settlement of our outstanding legal actions.
(3) Total 2008 R&D consists of internal R&D anticipated to be in the
|SOURCE Warner Chilcott Limited|
Copyright©2008 PR Newswire.
All rights reserved